CytomX Therapeutics ROE 2014-2022 | CTMX
Current and historical return on equity (ROE) values for CytomX Therapeutics (CTMX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| CytomX Therapeutics ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-09-30 |
$-0.10B |
$0.03B |
-165.81% |
| 2022-06-30 |
$-0.10B |
$0.05B |
-122.01% |
| 2022-03-31 |
$-0.09B |
$0.07B |
-92.00% |
| 2021-12-31 |
$-0.08B |
$0.09B |
-70.29% |
| 2021-09-30 |
$-0.07B |
$0.11B |
-66.51% |
| 2021-06-30 |
$-0.07B |
$0.13B |
-69.33% |
| 2021-03-31 |
$-0.06B |
$0.15B |
-81.85% |
| 2020-12-31 |
$-0.03B |
$0.05B |
-59.91% |
| 2020-09-30 |
$-0.05B |
$0.05B |
-94.74% |
| 2020-06-30 |
$-0.06B |
$0.06B |
-96.18% |
| 2020-03-31 |
$-0.08B |
$0.07B |
-99.67% |
| 2019-12-31 |
$-0.10B |
$0.05B |
-113.97% |
| 2019-09-30 |
$-0.10B |
$0.08B |
-90.41% |
| 2019-06-30 |
$-0.10B |
$0.10B |
-76.26% |
| 2019-03-31 |
$-0.08B |
$0.12B |
-72.41% |
| 2018-12-31 |
$-0.08B |
$0.13B |
-87.37% |
| 2018-09-30 |
$-0.05B |
$0.16B |
-62.70% |
| 2018-06-30 |
$-0.04B |
$0.04B |
-71.84% |
| 2018-03-31 |
$-0.05B |
$0.05B |
-90.32% |
| 2017-12-31 |
$-0.04B |
$0.07B |
-69.71% |
| 2017-09-30 |
$-0.06B |
$0.05B |
-91.57% |
| 2017-06-30 |
$-0.06B |
$0.05B |
-84.64% |
| 2017-03-31 |
$-0.05B |
$0.07B |
-59.65% |
| 2016-12-31 |
$-0.06B |
$0.08B |
-61.94% |
| 2016-09-30 |
$-0.06B |
$0.09B |
-53.15% |
| 2016-06-30 |
$-0.06B |
$0.10B |
-58.02% |
| 2016-03-31 |
$-0.05B |
$0.11B |
-69.86% |
| 2015-12-31 |
$-0.04B |
$0.13B |
-96.09% |
| 2015-06-30 |
$-0.02B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.115B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
